Gemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa study

Basit Öğe Kaydı
dc.contributor.authorStrumberg, D.
dc.contributor.authorSchultheis, B.
dc.contributor.authorEbert, M. P.
dc.contributor.authorSiveke, J.
dc.contributor.authorKerkhoff, A.
dc.contributor.authorBerdel, W.
dc.contributor.authorHofheinz, R.
dc.contributor.authorBehringer, D. M.
dc.contributor.authorSchmidt, W. E.
dc.contributor.authorGoker, E.
dc.contributor.authorDe Dosso, S.
dc.contributor.authorKneba, M.
dc.contributor.authorYalcin, S.
dc.contributor.authorOverkamp, F.
dc.contributor.authorSchlegel, F.
dc.contributor.authorDommach, M.
dc.contributor.authorRohrberg, R.
dc.contributor.authorSteinmetz, T.
dc.contributor.authorReuter, D.
dc.contributor.authorBach, F.
dc.date.accessioned2019-10-27T22:05:21Z
dc.date.available2019-10-27T22:05:21Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.identifier.endpage57en_US
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.startpage57en_US
dc.identifier.urihttps://hdl.handle.net/11454/48369
dc.identifier.volume37en_US
dc.identifier.wosWOS:000332306700187en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology Research and Treatmenten_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleGemcitabine and the monoclonal antibody nimotuzumab versus gemcitabine and placebo for the treatment of chemotherapy-naive patients (pts) with advanced pancreatic cancer (PC): A multicentre, randomized phase IIb/IIIa studyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu